Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Celltrion, Inc., Samsung Bioepis Co., Ltd.

N OTE: This order is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
REGENERON PHARMACEUTICALS, INC.,
Appellant
v.
MYLAN PHARMACEUTICALS INC., CELLTRION,
INC., SAMSUNG BIOEPIS CO., LTD.,
Appellees
______________________
2024-1564, 2024-1567
______________________
Appeals from the United States Patent and Trademark
Office, Patent Trial and Appeal Board in Nos. IPR2022-
01225, IPR2022-01226, IPR2023-00532, IPR2023-00533,
and IPR2023-00566.
______________________
ON MOTION
______________________
O R D E R
Upon consideration of Regeneron Pharmaceuticals,
Inc.’s unopposed motion to voluntarily dismiss the above-
captioned appeals pursuant to Federal Rule of Appellate
Procedure 42,
Case: 24-1564 Document: 28 Page: 1 Filed: 08/20/2024

-- 1 of 2 --

REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC.
2
I T I S O RDERED T HAT :
(1) The motion is granted, and the appeals are dis-
missed.
(2) Each party shall bear its own costs for each appeal.
August 20, 2024
Date
F OR THE COURT
ISSUED AS A MANDATE: August 20, 2024
Case: 24-1564 Document: 28 Page: 2 Filed: 08/20/2024

-- 2 of 2 --